comparemela.com

Latest Breaking News On - Proffered paper oral presentation - Page 1 : comparemela.com

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

Sugemalimab is the world s first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic.

Hong kongJason yangCaicun zhouCstone pharmaceuticalsPfizer incPrnewswire cstone pharmaceuticalsNational medical products administrationTongji universityDepartment of oncologyPrincipal investigatorShanghai pulmonary hospitalChief medical officerGreater chinaProffered paper oral presentationLate breaking abstractMini oral presentation

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

Sugemalimab is the world s first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic.

Hong kongJason yangCaicun zhouCstone pharmaceuticalsPfizer incPrnewswire cstone pharmaceuticalsNational medical products administrationTongji universityDepartment of oncologyPrincipal investigatorShanghai pulmonary hospitalChief medical officerGreater chinaProffered paper oral presentationLate breaking abstractMini oral presentation

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients - read this article along with other careers information, tips and advice on BioSpace

Hong kongJason yangCaicun zhouCstone pharmaceuticalsPfizer incPrnewswire cstone pharmaceuticalsSource cstone pharmaceuticalsNational medical products administrationTongji universityDepartment of oncologyPrincipal investigatorShanghai pulmonary hospitalChief medical officerGreater chinaProffered paper oral presentationLate breaking abstract

CStone Pharmaceuticals: CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

SUZHOU, China, Dec. 21, 2021 /PRNewswire/ CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has

Jason yangCaicun zhouFrank jiangU ligand corporationPrnewswire cstone pharmaceuticals the companyDrug administrationNational medical products administrationShareholders of the companyDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater chinaProffered paper oral presentation

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Jason yangCaicun zhouFrank jiangSource cstone pharmaceuticalsDrug administrationShareholders of the companyU ligand corporationPrnewswire cstone pharmaceuticals the companyNational medical products administrationDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater china

vimarsana © 2020. All Rights Reserved.